arXivDaily arXiv每日学术速递 周一至周五更新
arXiv周末暂无论文更新,休息一下吧,周末愉快~~
arXiv 2401.17157eess.SYcs.SY
收藏

基于CHoKI的人工胰腺血糖调节模型预测控制(MPC)

CHoKI-based MPC for blood glucose regulation in Artificial Pancreas

Beatrice Sonzogni, José María Manzano, Marco Polver, Fabio Previdi, Antonio Ferramosca

AI总结:

本研究针对人工胰腺的血糖调节问题,采用CHoKI数据驱动方法构建个性化MPC控制器,经UVA/Padova虚拟患者测试,该方法可减少低血糖时间,满足血糖达标要求,避免长期高血糖。

摘要:

本研究提出了一种应用于人工胰腺的模型预测控制(MPC)方法,能够自主管理1型糖尿病患者的基础胰岛素注射。具体而言,该MPC的目标是将患者的血糖水平维持在70-180 mg/dL的安全范围内,通过调整胰岛素用量并满足所有既定约束,同时考虑在体胰岛素(Insulin On Board, IOB)以避免胰岛素输注过量。MPC依赖模型对系统行为进行预测,而由于糖尿病病情复杂,通用生理模型的识别难度较大,因此本研究采用数据驱动的学习方法替代传统生理模型。研究采用分量式赫尔德奇异推理(Componentwise Hölder Kinky Inference, CHoKI)方法,为每位患者定制个性化控制器。在数据采集阶段及控制器测试环节,均使用了经FDA认可的UVA/Padova模拟器中的虚拟患者。此外,研究还在考虑了胰岛素敏感性变异性的修改版模拟器上对所提MPC进行了测试。最终结果令人满意:与模拟器提供的标准恒定基础胰岛素治疗结果相比,该控制器减少了患者处于低血糖(危险性更高)状态的时间,同时满足了血糖在目标范围内的时间要求,且避免了长期高血糖事件的发生。

英文摘要:

This work presents a Model Predictive Control (MPC) for the artificial pancreas, which is able to autonomously manage basal insulin injections in type 1 diabetic patients. Specifically, the MPC goal is to maintain the patients' blood glucose level inside the safe range of 70-180 mg/dL, acting on the insulin amount and respecting all the imposed constraints, taking into consideration also the Insulin On Board (IOB), to avoid excess of insulin infusion. MPC uses a model to make predictions of the system behaviour. In this work, due to the complexity of the diabetes disease that complicates the identification of a general physiological model, a data-driven learning method is employed instead. The Componentwise Hölder Kinky Inference (CHoKI) method is adopted, to have a customized controller for each patient. For the data collection phase and also to test the proposed controller, the virtual patients of the FDA-accepted UVA/Padova simulator are exploited. The proposed MPC is also tested on a modified version of the simulator, that takes into consideration also the variability of the insulin sensitivity. The final results are satisfying since the proposed controller reduces the time in hypoglycemia (which is more dangerous) if compared to the outcome obtained with the standard constant basal insulin therapy provided by the simulator, satisfying also the time in range requirements and avoiding long-term hyperglycemia events.

机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。

↑